Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 14/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25389429 | 0.99 | MAPT (0.45) | SIRT2MAPTRXFP1L3MBTL1TBXAS1 | |
| SCHEMBL25389258 | 0.99 | MAPT (0.45) | SIRT2MAPTRXFP1L3MBTL1TBXAS1 | |
| SCHEMBL25310574 | 0.99 | MAPT (0.45) | SIRT2MAPTRXFP1L3MBTL1TBXAS1 | |
| SCHEMBL25390529 | 0.99 | MAPT (0.45) | SIRT2MAPTRXFP1L3MBTL1TBXAS1 | |
| SCHEMBL9263718 | 0.96 | SIRT2 (0.45) | SIRT2MAPTRXFP1L3MBTL1TBXAS1 | |
| SCHEMBL8448421 | 0.91 | SIRT2 (0.43) | SIRT2TBXAS1 | |
| SCHEMBL877785 | 0.90 | SIRT2 (0.46) | SIRT2 | |
| Hydrochloric Acid SCHEMBL8892437 | 0.89 | SIRT2 (0.46) | SIRT2 | |
| SCHEMBL9521352 | 0.88 | SIRT2 (0.44) | SIRT2L3MBTL1 | |
| SCHEMBL27569457 | 0.88 | SIRT2 (0.41) | SIRT2MAPTRXFP1L3MBTL1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161476-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2025-05-22 | — | — | US | disclosed |
| US-12280124-B2 | Antibody-drug conjugates comprising GLP1 peptidomimetics and uses thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| EP-4489855-A1 | ANTI-GLP1R ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| US-20230330254-A1 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230330254-A1 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| WO-2023173132-A1 | ANTI-GLP1R ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| CN-116615251-A | Antibody-drug conjugates comprising GLP1 peptide mimetics and the uses thereof | 瑞泽恩制药公司 | 2023-08-18 | — | — | CN | disclosed |
| EP-4210767-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20220096648-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | US | disclosed |
| WO-2022056494-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
| CN-1571796-A | Melanocortin receptor ligands | PROCTER & GAMBLE (US) | 2005-01-26 | — | — | CN | disclosed |
| US-6355665-B1 | ANTIHISTAMINES, ANTIALLERGENS AND IRRITABLE BOWEL SYNDROME. | JAMES BLACK FOUNDATION LIMITED (GB) | 2002-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220096648-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | GLP1R, GIPR, GCGR | SIRT2 1935/4885MAPT 2627/4885RXFP1 24/4885 |
| US-20250161476-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | GLP1R, GIPR, GCGR | SIRT2 1935/4885MAPT 2627/4885RXFP1 24/4885 |
| US-12280124-B2 | Antibody-drug conjugates comprising GLP1 peptidomimetics and uses thereof | GLP1R, GIPR, GCGR | SIRT2 1935/4885MAPT 2627/4885RXFP1 24/4885 |
| US-20230330254-A1 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | GLP1R, GIPR, GCGR | SIRT2 1289/4885MAPT 2902/4885RXFP1 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.